GlassScriptPhysician profile
Jeffrey A Frey
NPI 1871581173
$5,915.12
in general payments reported to CMS, 2019-2025
27 companies · $910 in 2025
The $910 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $553 · 2021: $1,057 · 2022: $851 · 2023: $786 · 2024: $935 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602 · Education: $29.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.73 |
| Education | $29.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,349.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $864.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $675.81 | 2019-2025 | |
| Lilly USA, LLC | $494.38 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $381.74 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $341.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $258.39 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.15 | 2022-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.68 | 2019-2023 | Stiolto Respimat |
| E.R. Squibb & Sons, L.L.C. | $167.77 | 2019-2024 | Eliquis |
| Nestle Healthcare Nutrition INC. | $118.52 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $116.70 | 2020-2022 | |
| Astellas Pharma US INC | $100.66 | 2019 | |
| Amgen INC. | $99.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $88.55 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $68.07 | 2019-2020 | |
| Sanofi Pasteur INC. | $57.63 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.06 | 2024-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $46.05 | 2021 | |
| Boston Scientific Corporation | $44.50 | 2025 | Watchman Access System |
| Exact Sciences Corporation | $38.67 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $25.92 | 2022 | |
| Aimmune Therapeutics, INC. | $19.33 | 2024 | |
| Amarin Pharma, INC. | $16.82 | 2020 | |
| Depuy Synthes Sales INC. | $16.52 | 2020 | |
| Seqirus USA INC | $14.54 | 2025 | Flucelvax, Fluad |
| Teva Pharmaceuticals USA, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Frey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.